Drugs / Pneumococcal polysaccharide vaccine 23 valent
Pneumococcal polysaccharide vaccine 23 valent
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT03039491 | Sep 2015 → Mar 2020 | lipodystrophy | Medical University of South Carolina | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pneumococcal polysaccharide vaccine 23 valent | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03039491 ↗ |
| Known as | Pneumovax-23 | “pneumococcal vaccination with either the 23-valent pneumococcal polysaccharide vaccine PPV-23 (Pneumovax-23) alone or the 13-valent pneumococcal conjugate vaccine PCV-13...” NCT03039491 ↗ |
| Known as | PPV-23 | “pneumococcal vaccination with either the 23-valent pneumococcal polysaccharide vaccine PPV-23 (Pneumovax-23) alone or the 13-valent pneumococcal conjugate vaccine PCV-13...” NCT03039491 ↗ |
| Modality | Vaccine | “This is the pneumococcal vaccine consisting of the capsular polysaccharides of 23 serotypes of Streptococcus pneumoniae” NCT03039491 ↗ |